Cancer Centers Report Sustained Shortages of Platinum Chemotherapies Forcing Treatment Modifications
Persistent platinum chemotherapy shortages have compelled regimen changes at a substantial fraction of US cancer centers, rooted in fragile generic supply chains. Observational tracking data from FDA and ASHP document prolonged disruptions without resolution. Policy fixes targeting manufacturing economics are under discussion but unproven at scale.
Regulatory proposals under consideration include advance purchase commitments and expedited inspections for new entrants, yet implementation timelines remain unclear. Next steps hinge on whether the 2024 manufacturing incentives produce measurable supply increases by mid-2025; without them, substitution and rationing protocols will likely persist.
FDA: Domestic cisplatin production capacity will rise at least 25% by Q4 2025 if new contract incentives are enacted.
Sources (3)
- [1]STAT News on Biotech Shortages(https://www.statnews.com/2026/09/11/biotech-news-cancer-drug-shortages-keep-disrupting-patient-care/)
- [2]FDA Drug Shortages Database(https://www.fda.gov/drugs/drug-safety-and-availability/drug-shortages)
- [3]ASHP National Drug Shortages Report(https://www.ashp.org/drug-shortages)